Patents by Inventor Mi-yeun Kim

Mi-yeun Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition for treating or preventing obesity
    Patent number: 11187696
    Abstract: Melanophilin (MLPH) of the present invention is involved in differentiation into an adipocyte or fat accumulation, and accordingly, obesity can be treated or prevented by inhibiting the MLPH. Further, by measuring an expression level of the MLPH, obesity can be diagnosed and treated, and therapeutic agents for obesity and agents regulating differentiation into adipocytes can be screened.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: November 30, 2021
    Assignee: KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES
    Inventors: Kee Ho Lee, Yang Hyun Kim, Eun Ran Park, Sung Sub Kim, Hyun Jin Shin, Eun Ju Lee, Chun Ho Kim, Sang Jun Park, Mi-yeun Kim, Jie Young Song
  • INHIBITORS OF PLRG1 (PLEIOTROPIC REGULATOR 1) FOR PREVENTING OR TREATING CANCER AND METHODS FOR MAKING AND USING THEM
    Publication number: 20180362986
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer containing pleiotropic regulator 1 (PLRG1) inhibitor as an active ingredient, a method for treating cancer including administering the composition to a subject, a composition for diagnosing cancer containing an agent for measuring the expression level of PLRG1, a method for providing information for diagnosing cancer including measuring the expression level of PLRG1, and a method for screening agents for preventing or treating cancer. Pleiotropic regulator 1 (PLRG1) is overexpressed in cancer cells, and the inhibition of the expression of PLRG1 can induce cancer cell-specific apoptosis. Accordingly, the PLRG1 inhibitor of the present invention has an excellent effect as an anticancer agent without side effects, and additionally, the PLRG1 inhibitor can be used for cancer diagnosis, screening of anticancer agents, etc. by measuring the expression levels of PLRG1.
    Type: Application
    Filed: October 7, 2016
    Publication date: December 20, 2018
    Inventors: Kee-Ho LEE, Sungsub KIM, Yeon-Soo KIM, Eun-Ran PARK, Hyun Jin SHIN, Eun-Ju LEE, Yong-Ho HAM, Sang Bum KIM, Sun-Hoo PARK, Chul-Ju HAN, Sung Hee HONG, Yang Hyun KIM, Jung Min KIM, Mi Yeun KIM, Moonkyoung KANG, Eun Yeong SONG, Jie Young SONG
  • A Pharmaceutical composition for treating or preventing obesity
    Publication number: 20180259502
    Abstract: Melanophilin (MLPH) of the present invention is involved in differentiation into an adipocyte or fat accumulation, and accordingly, obesity can be treated or prevented by inhibiting the MLPH. Further, by measuring an expression level of the MLPH, obesity can be diagnosed and treated, and therapeutic agents for obesity and agents regulating differentiation into adipocytes can be screened.
    Type: Application
    Filed: August 18, 2016
    Publication date: September 13, 2018
    Inventors: Kee Ho Lee, Yang Hyun Kim, Eun Ran Park, Sung Sub Kim, Hyun Jin Shin, Eun Ju Lee, Chun Ho Kim, Sang Jun Park, Mi-yeun Kim, Jie Young Song